Skip to main content
For Healthcare Professionals

Reset all filters

61 - 70 of 102 results

Publications

Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.

Presentation

Primary Phase Ib analysis of Beamion™ LUNG-1: zongertinib (BI 1810631) in patients with HER2-mutant NSCLC
Primary Phase Ib analysis of Beamion™ LUNG-1: Zongertinib (BI 1810631) in patients with HER2-mutant NSCLC
Author(s): Ruiter et al.
NSCLC HER2 TKI Presentation
Download
Phase I trial of DLL3/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumours: patients with LCNEC-L
Phase I trial of DLL3/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with DLL3-positive tumours: patients with LCNEC-L
Author(s): Wermke et et al.
LCNEC-L DLL3/CD3 TcE Presentation
Download
Zongertinib in Patients with HER2-Mutant NSCLC: Updated Analysis of Beamion™ LUNG-1
Zongertinib in Patients with HER2-Mutant NSCLC: Updated Analysis of Beamion™ LUNG-1
Author(s): Yamamoto et al.
NSCLC HER2 TKI Presentation
Download
Zongertinib (BI 1810631) in patients with HER2-driven tumors: Phase Ia and Phase Ib analysis of Beamion™ LUNG-1
Zongertinib (BI 1810631) in Patients with HER2-Driven Tumors: Phase Ia and Phase Ib Analysis of Beamion™ LUNG-1
Author(s): Wu et al.
NSCLC, Solid tumors HER2 TKI Presentation
Download
Zongertinib (BI 1810631) for HER2-positive solid tumors with brain metastases: subanalysis of the Beamion LUNG-1 trial
Zongertinib (BI 1810631) for HER2-positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion™ LUNG-1 Trial
Author(s): Opdam et al.
NSCLC, Solid tumors HER2 TKI Presentation
Download
Primary Phase Ib analysis of Beamion™ LUNG-1: zongertinib (BI 1810631) in patients with HER2 mutation-positive NSCLC
Phase Ib analysis of Beamion™ LUNG-1: Zongertinib (BI 1810631) in Patients with HER2-Mutant NSCLC
Author(s): Ruiter et al.
NSCLC HER2 TKI Presentation
Download
Phase I trial of DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumors: patients with LCNEC-L
Phase I Trial of DLL3/CD3 IgG-like T-cell Engager Obrixtamig (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC-L
Author(s): Wermke et al.
LCNEC-L DLL3/CD3 TcE Presentation
Download
Target engagement and saturating effects demonstrated with quantitative 89Zr-PET imaging for the therapeutic anti-SIRPα antibody BI 765063
Target Engagement and Saturating Effects demonstrated with quantitative 89Zr-PET imaging for the Therapeutic Anti-SIRPα Antibody BI 765063
Author(s): Pouw et al.
Solid tumors SIRPα antagonist Presentation
Download
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI) in patients (pts) with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion™ LUNG-1, including progression-free survival (PFS) data
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor in patients with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion™ LUNG-1, including progression-free survival data
Author(s): Heymach et al.
Solid tumors HER2 TKI Presentation
Download
Updated data from a Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: focus on extrapulmonary neuroendocrine carcinomas (epNECs)
Updated data from a Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumours: focus on extrapulmonary neuroendocrine carcinomas
Author(s): Capdevila et al.
NEC/epNEC DLL3/CD3 TcE Presentation
Download